Cantor Fitzgerald initiated coverage of Bright Minds Biosciences (DRUG) with an Overweight rating and no price target The company’s emerging pipeline is poised to deliver uncommon clinical value targeting high unmet medical needs in rare epilepsies and central nervous system disorders, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRUG:
- Bright Minds Biosciences initiated with a Buy at H.C. Wainwright
- Bright Minds Biosciences Appoints New Chief Medical Officer to Advance CNS Therapeutics
- Bright Minds Biosciences appoints Stephen Collins as Chief Medical Officer
- Bright Minds Biosciences (DRUG) Finishes the Year with Phenomenal Share Price Increase
- Bright Minds Biosciences initiated with an Outperform at Baird